September 5, 2014
1 min read

Paper on improved antibody tag in Molecular Pharmaceutics

Developing an antibody tag with improved pharmacokinetics and stability allowed Tagworks to achieve increased tumor uptake of a radiolabeled pretargeting probe. Even though this adapted tag exhibited a slight loss in reactivity, its use in a antibody (CC49-TCO) conjugate demonstrated a longer clearance half-life, improved tumor accumulation and increased in vivo stability. The overall result was a 50% increase in tumor uptake as well as increased tumor/non-tumor ratios of the radiolabeled tetrazine probe. Read the Tagworks paper "Trans-cyclooctene tag with improved properties for tumor pretargeting with the Diels-Alder reaction" in Mol. Pharmaceutics 2014, 11(9). doi:10.1021/mp500725a

Curious about what we do? Get in touch!


About    Our Technology   Pipeline    Join us    News    Contact

T +31 85 800 8550

Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2024 | Terms of use | Design by Ape to Zebra